Structure-based identification of novel ligands targeting multiple sites within a chemokine-G protein-coupled receptor interface (original) (raw)
Related papers
Structural basis of ligand interaction with atypical chemokine receptor 3
Nature communications, 2017
Chemokines drive cell migration through their interactions with seven-transmembrane (7TM) chemokine receptors on cell surfaces. The atypical chemokine receptor 3 (ACKR3) binds chemokines CXCL11 and CXCL12 and signals exclusively through β-arrestin-mediated pathways, without activating canonical G-protein signalling. This receptor is upregulated in numerous cancers making it a potential drug target. Here we collected over 100 distinct structural probes from radiolytic footprinting, disulfide trapping, and mutagenesis to map the structures of ACKR3:CXCL12 and ACKR3:small-molecule complexes, including dynamic regions that proved unresolvable by X-ray crystallography in homologous receptors. The data are integrated with molecular modelling to produce complete and cohesive experimentally driven models that confirm and expand on the existing knowledge of the architecture of receptor:chemokine and receptor:small-molecule complexes. Additionally, we detected and characterized ligand-induced...
Experimental Biology and Medicine, 2011
Understanding the structural mechanism of receptor–ligand interactions for the chemokine receptor CXCR4 is essential for determining its physiological and pathological functions and for developing new therapies targeted to CXCR4. We have recently reported a structural mechanism for CXCR4 antagonism by a novel synthetic CXCR4 antagonist RCP168 and compared its effectiveness against the natural agonist SDF-1 α. In the present study, using molecular docking, we further investigate the binding modes of another seven small molecules known to act as CXCR4 antagonists. The predicted binding modes were compared with previously published mutagenesis data for two of these (AMD3100 and AMD11070). Four antagonists, including AMD3100, AMD11070, FC131 and KRH-1636, bound in a similar fashion to CXCR4. Two important acidic amino acid residues (Asp262 and Glu288) on CXCR4, previously found essential for AMD3100 binding, were also involved in binding of the other ligands. These four antagonists use ...
Peptides targeting chemokine receptor CXCR4: structural behavior and biological binding studies
Journal of Peptide Science, 2014
mechanisms: (i) hypoxic conditions within solid tumors may induce CXCR4 expression via hypoxia-inducible factor 1α or (ii) vascular endothelial growth factor produced by tumor cells may induce CXCR4 expression on the tumor cell itself and/or on tumor-associated endothelial cells that facilitate both angiogenesis and metastasis of primary tumor [20]. Because CXCR4 is overexpressed in several human cancers, the blockade of CXCR4-CXCL12 interactions has been extensively investigated as a potential cancer therapeutic [21]. The lead CXCR4 antagonist, plerixafor (previously known as AM D3100), is the most clinically advanced compound. Since December 2008, it is an FDA-approved drug, in combination with granulocyte colony-stimulating factor, for hematopoietic stem and progenitor cell mobilization in patients with non-Hodgkin lymphoma and multiple myeloma [22] even if it is a metal-chelating bicyclam that has been shown to determine cardiotoxicity as reported in its clinical trial against HIV [23]. Therefore, this suggests the need for new antagonists able to block, without any other compliance, the binding between CXCL12 and CXCR4 and/or that between CXCL12 and CXCR7. As the in silico modeling provides a time-effective and cost-effective tool for the screening of molecules as well as for the design of novel molecules of desired activity, we have focused on CXCL12 and performed a ligand-based approach to design new CXCR4 peptidic antagonists suitable for anticancer therapy. Therefore, we have modeled the 3D structure of CXCR4 and its complex with CXCL12, designed and synthesized two peptides, using as template the N-terminal region of CXCL12, analyzed computationally and experimentally their structure, and then evaluated their interaction with CXCR4 by in vitro studies and docking approaches.
Structural Analysis of a Novel Small Molecule Ligand Bound to the CXCL12 Chemokine
Journal of Medicinal Chemistry, 2014
CXCL12 binds to CXCR4, promoting both chemotaxis of lymphocytes and metastasis of cancer cells. We previously identified small molecule ligands that bind CXCL12 and block CXCR4-mediated chemotaxis. We now report a 1.9 Å resolution X-ray structure of CXCL12 bound by such a molecule at a site normally bound by sY21 of CXCR4. The complex structure reveals binding hot spots for future inhibitor design and suggests a new approach to targeting CXCL12−CXCR4 signaling in drug discovery.
Angewandte Chemie (International ed. in English), 2016
The chemokine receptor CXCR3 is a G protein-coupled receptor that conveys extracellular signals into cells by changing its conformation upon ligand binding. We previously hypothesized that small-molecule allosteric CXCR3-agonists do not bind to the same allosteric binding pocket as 8-azaquinazolinone-based negative allosteric modulators. We have now performed molecular-dynamics (MD) simulations with metadynamics enhanced sampling on the CXCR3 system to refine structures and binding modes and to predict the CXCR3-binding affinities of the biased allosteric agonist FAUC1036 and the negative allosteric modulator RAMX3. We have identified two distinct binding sites; a "shallow" and a second "deeper" pocket to which the biased allosteric agonist FAUC1036 and negative allosteric modulator RAMX3 bind, respectively.
Current Topics in Medicinal Chemistry, 2013
The chemokine CXCL12 and its G protein-coupled receptor (GPCR) CXCR4 are high-priority clinical targets because of their involvement in metastatic cancers (also implicated in autoimmune disease and cardiovascular disease). Because chemokines interact with two distinct sites to bind and activate their receptors, both the GPCRs and chemokines are potential targets for small molecule inhibition. A number of chemokines have been validated as targets for drug development, but virtually all drug discovery efforts focus on the GPCRs. However, all CXCR4 receptor antagonists with the exception of MSX-122 have failed in clinical trials due to unmanageable toxicities, emphasizing the need for alternative strategies to interfere with CXCL12/CXCR4-guided metastatic homing. Although targeting the relatively featureless surface of CXCL12 was presumed to be challenging, focusing efforts at the sulfotyrosine (sY) binding pockets proved successful for procuring initial hits. Using a hybrid structure-based in silico/NMR screening strategy, we recently identified a ligand that occludes the receptor recognition site. From this initial hit, we designed a small fragment library containing only nine tetrazole derivatives using a fragment-based and bioisostere approach to target the sY binding sites of CXCL12. Compound binding modes and affinities were studied by 2D NMR spectroscopy, X-ray crystallography, molecular docking and cell-based functional assays. Our results demonstrate that the sY binding sites are conducive to the development of high affinity inhibitors with better ligand efficiency (LE) than typical protein-protein interaction inhibitors (LE ≤ 0.24). Our novel tetrazolebased fragment 18 was identified to bind the sY21 site with a K d of 24 M (LE = 0.30). Optimization of 18 yielded compound 25 which specifically inhibits CXCL12-induced migration with an improvement in potency over the initial hit 9. The fragment from this library that exhibited
Identification and profiling of CXCR3-CXCR4 chemokine receptor heteromer complexes
British Journal of Pharmacology, 2013
The C-X-C chemokine receptors 3 (CXCR3) and C-X-C chemokine receptors 4 (CXCR4) are involved in various autoimmune diseases and cancers. Small antagonists have previously been shown to cross-inhibit chemokine binding to CXCR4, CC chemokine receptors 2 (CCR2) and 5 (CCR5) heteromers. We investigated whether CXCR3 and CXCR4 can form heteromeric complexes and the binding characteristics of chemokines and small ligand compounds to these chemokine receptor heteromers.
Ligand Selectivity and Affinity of Chemokine Receptor CXCR1
Journal of Biological Chemistry, 2004
Glu-Leu-Arg ("ELR") CXC chemokines interleukin-8 (IL-8) and melanoma growth stimulatory activity (MGSA) recruit neutrophils by binding and activating two receptors, CXCR1 and CXCR2. CXCR1 is specific, binding only IL-8 with nanomolar affinity, whereas CXCR2 is promiscuous, binding all ELRCXC chemokines with high affinity. Receptor signaling consists of two events: interactions between the ligand N-terminal loop (N-loop) and receptor N-terminal domain (N-domain) residues (site I), and between the ligand N-terminal ELR and the receptor juxtamembrane domain (Jdomain) residues (site II). It is not known how these interactions mediate ligand affinity and selectivity, and whether binding at one site influences binding and function at the other. Sequence analysis and structure-function studies have suggested that the receptor N-domain plays an important role in ligand selectivity. Here, we report ligand-binding properties and structural characteristics of the CXCR1 N-domain in solution and in detergent micelles that mimic the native membrane environment. We find that IL-8 binds the N-domain with significantly higher affinity in micelles than in solution (ϳ1 M versus ϳ20 M) and that MGSA does not bind the N-domain in solution but does in micelles with appreciable affinity (ϳ3 M). We find that the N-domain is structured in micelles and that the entire N-domain interacts with the micelle in an extended fashion. We conclude that the micellar environment constrains the Ndomain, and this conformational restraint influences its ligand-binding properties. Most importantly, our data suggest that for both ligands, site I interaction provides similar affinity and that differential coupling between site I and II interactions is responsible for the observed differences in affinity. Chemokines, or chemotactic cytokines, are small soluble proteins (70-120 residues) that play fundamental regulatory roles in native immunity, inflammation, and host defense against infection. Over 40 chemokines have been identified to date, and these can be classified as CC, CXC, C, or CX 3 C chemokines based on the position of conserved cysteines (1). The CXC